Li FM, Xu DY, Xu Q, Yuan Y. Breast-conserving surgery and sentinel lymph node biopsy for breast cancer and their correlation with the expression of polyligand proteoglycan-1. World J Clin Cases 2022; 10(10): 3113-3120 [PMID: 35647115 DOI: 10.12998/wjcc.v10.i10.3113]
Corresponding Author of This Article
Fu-Ming Li, MHSc, Associate Chief Physician, Department of Breast Surgery, The Second Hospital of Jiaxing, No. 1518 Huancheng North Road, Nanhu District, Jiaxing 314000, Zhejiang Province, China. doclfm@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 6, 2022; 10(10): 3113-3120 Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3113
Breast-conserving surgery and sentinel lymph node biopsy for breast cancer and their correlation with the expression of polyligand proteoglycan-1
Fu-Ming Li, Dan-Ying Xu, Qi Xu, Yan Yuan
Fu-Ming Li, Dan-Ying Xu, Qi Xu, Yan Yuan, Department of Breast Surgery, The Second Hospital of Jiaxing, Jiaxing 314000, Zhejiang Province, China
Author contributions: Li FM and Xu DY contributed equally to this work and are considered co-first authors; Li FM and Xu DY analyzed and interpreted data and wrote the manuscript; Xu Q and Yuan Y drafted the manuscript and collected the data; Li FM designed the study and revised the manuscript for important intellectual content.
Supported byJiaxing Science and Technology Project, No. 2021AD30119.
Institutional review board statement: The study was reviewed and approved by the Jiaxing Second Hospital Institutional Review Board (Approval No. JXEY-2021JX005).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Dr. Li FM reports grants from Jiaxing Science and Technology Project, during the conduct of the study. No other conflict-of-interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Ming Li, MHSc, Associate Chief Physician, Department of Breast Surgery, The Second Hospital of Jiaxing, No. 1518 Huancheng North Road, Nanhu District, Jiaxing 314000, Zhejiang Province, China. doclfm@163.com
Received: December 20, 2021 Peer-review started: December 20, 2021 First decision: January 18, 2022 Revised: February 6, 2022 Accepted: February 20, 2022 Article in press: February 20, 2022 Published online: April 6, 2022 Processing time: 99 Days and 1.2 Hours
ARTICLE HIGHLIGHTS
Research background
Breast cancer is a malignant tumor with an unclear etiology and is the most common malignant tumor in women.
Research motivation
Polyligand proteoglycan-1 [syndecan-1 (SDC-1)] participates in the regulation of various functions, including lymphocyte accumulation, immunomodulation, and cell matrix regulation, and is closely related to the progress of various malignant tumors.
Research objectives
We explored the efficacy of different treatment methods and their correlation with SDC-1 expression.
Research methods
We selected 80 patients with breast cancer and divided into an observation group (n = 44) and control group (n = 36) according to the treatment plan.
Research results
The positive expression rate of SDC-1 in patients with American Joint Committee on Cancer (AJCC) stage II was 11.29%, which was significantly lower than that for AJCC stage I.
Research conclusions
Low SDC-1 expression in breast cancer lesions is related to AJCC staging.
Research perspectives
We need further multicenter studies with large samples to confirm this study.
